series-a
Stage
2
Investors
About
EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing glasmacinal, an oral non-antibiotic macrolide designed to reduce exacerbations in COPD patients by retaining macrolide anti-inflammatory and host-defense properties without promoting antimicrobial resistance.
Explore EpiEndo Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.